Miyashita Naoyuki, Horita Nobuyuki, Nakamori Yasushi, Ogata Makoto, Fukuda Naoki, Yamura Akihisa, Ito Tomoki
First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Hirakata, Japan.
Chemotherapy Center, Yokohama City University Hospital, Yokohama, Japan.
Microbiol Spectr. 2025 Apr 15;13(5):e0340724. doi: 10.1128/spectrum.03407-24.
In the post-acute coronavirus disease 2019 (COVID-19) period, patients with asthma had a significantly higher risk of cough than patients without a history of asthma. In particular, cases with persistent cough were increased during the Omicron variant epidemic. In this study, we evaluated the efficacy of ensitrelvir for the treatment of cough associated with COVID-19 Omicron variants in patients with asthma. This follows the Strengthening the Reporting of Observational Studies in Epidemiology statement. A total of 223 patients were registered in this study: 121 patients chose ensitrelvir, and 102 patients chose symptomatic treatment. Cough severity, frequency, and cough-specific quality of life were evaluated using the Japanese version of the Leicester Cough Questionnaire (J-LCQ). J-LCQ documented at baseline on days 4, 7, and 14 for all patients showed a steady improvement over time in both groups. In the mixed model for repeated measures model, which accounts for repeated measurements, the change in J-LCQ score from baseline was 2.1 points higher in the ensitrelvir group ( <0.001). Additionally, patients who were using triple inhaled therapy at baseline showed a 2.3-point higher change in J-LCQ score from baseline ( <0.001). Multiple regression analysis was performed at days 4, 7, and 14, with the change in J-LCQ score from baseline as the dependent variable. Ensitrelvir was associated with scores that were 3.1 points higher on day 4, 3.5 points higher on day 7, and 2.0 points higher on day 14 compared with symptomatic treatment ( <0.001 for all). In conclusion, our results demonstrated that early administration of ensitrelvir may be effective as a treatment for cough due to the COVID-19 Omicron variant.
We evaluated the efficacy of ensitrelvir for the treatment of cough due to coronavirus disease 2019 (COVID-19) Omicron variant in patients with asthma. A total of 223 patients were registered in this study: 121 patients chose ensitrelvir, and 102 patients chose symptomatic treatment. Cough severity, frequency, and cough-specific quality of life were evaluated using the Japanese version of the Leicester Cough Questionnaire (J-LCQ). Multiple regression analysis was performed at days 4, 7, and 14, with the change in J-LCQ score from baseline as the dependent variable. Ensitrelvir was associated with scores that were 3.1 points higher on day 4, 3.5 points higher on day 7, and 2.0 points higher on day 14 compared with symptomatic treatment ( <0.001 for all). Our results demonstrated that early administration of ensitrelvir may be effective as a treatment for cough due to the COVID-19 Omicron variant.
在2019年冠状病毒病（COVID-19）急性后期，哮喘患者咳嗽的风险显著高于无哮喘病史的患者。特别是在奥密克戎变异株流行期间，持续性咳嗽的病例有所增加。在本研究中，我们评估了恩昔洛韦治疗哮喘患者中与COVID-19奥密克戎变异株相关咳嗽的疗效。本研究遵循加强流行病学观察性研究报告声明。本研究共纳入223例患者：121例患者选择恩昔洛韦，102例患者选择对症治疗。使用日本版莱斯特咳嗽问卷（J-LCQ）评估咳嗽严重程度、频率和咳嗽特异性生活质量。所有患者在基线、第4天、第7天和第14天记录的J-LCQ显示，两组随时间均有稳步改善。在考虑重复测量的重复测量混合模型中，恩昔洛韦组J-LCQ评分较基线的变化高2.1分（<0.001）。此外，基线时使用三联吸入疗法的患者J-LCQ评分较基线的变化高2.3分（<0.001）。在第4天、第7天和第14天进行多元回归分析，以J-LCQ评分较基线的变化作为因变量。与对症治疗相比，恩昔洛韦在第4天的评分高3.1分，第7天高3.5分，第14天高2.0分（均<0.001）。总之，我们的结果表明，早期给予恩昔洛韦可能对治疗COVID-19奥密克戎变异株引起的咳嗽有效。
我们评估了恩昔洛韦治疗哮喘患者中由2019年冠状病毒病（COVID-19）奥密克戎变异株引起咳嗽的疗效。本研究共纳入223例患者：121例患者选择恩昔洛韦，102例患者选择对症治疗。使用日本版莱斯特咳嗽问卷（J-LCQ）评估咳嗽严重程度、频率和咳嗽特异性生活质量。在第4天、第7天和第14天进行多元回归分析，以J-LCQ评分较基线的变化作为因变量。与对症治疗相比，恩昔洛韦在第4天的评分高3.1分，第7天高3.5分，第14天高2.0分（均<0.001）。我们的结果表明，早期给予恩昔洛韦可能对治疗COVID-19奥密克戎变异株引起的咳嗽有效。
